THERAPEUTIC TARGETING OF THE HHLA2/KIR3DL3 AXIS AS A NOVEL IMMUNE CHECKPOINT PATHWAY IN RENAL CANCER.

$972,927FY2021Defense Health AgencyDOD

Beth Israel Deaconess Medical Center, Inc.

Investigators